REPROCELL
Biotechnology Research • 
Yokohama City, Kanagawa, Japan • 51-100 Employees
Company overview
| Headquarters | 8F KDX Shin-Yokohama 381 Bldg., 3-8-11,Shin-Yokohama, Kohoku-ku, Yokohama, 222-0033, JP |
| Website | |
| NAICS | 541714 |
| SIC | 873 |
| Keywords | Human Tissue, Stem Cell Technology, Ipsc Services, Drug Discovery Services, Covid-19 Samples, Human Clinical Samples For Research, Ipsc Diffirentiation, Ipsc Reprogramming, Ipsc Technologies |
| Founded | 2003 |
| Employees | 51-100 |
| Socials |
Key Contacts at REPROCELL
Chirag Tawde
Sales Director Emea
Nikola Kolundzic
Analytical Project Manager, Study Director, And Senior Stem Cell Scientist
Jean-Philippe Richard
Stem Cell Director
Cristina Linde
Senior Scientist And Study Director
Graeme Macluskie
Director Of Precision Medicine
Lee Christie
Study Director, Reprocell Europe Ltd
Michael Finch
Study Director
Chikafumi Yokoyama
Chief Executive Officer
Rj Lucas
Director Of Operations - Stem Cell Products
REPROCELL Email Formats
REPROCELL uses 5 email formats. The most common is {first initial}.{last name} (e.g., j.doe@reprocell.com), used 70.5% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@reprocell.com | 70.5% |
{first name}.{last name} | john.doe@reprocell.com | 18.2% |
{last name} | doe@reprocell.com | 4.5% |
{first initial}{last name} | jdoe@reprocell.com | 2.3% |
{first initial} | j@reprocell.com | 2.3% |
About REPROCELL
REPROCELL supports nearly the entire workflow of stem cell research and pre-clinical drug development. Our unique portfolio includes access to human tissues (BioServe) and human tissue testing (Biopta), in addition to stem cell culture media, reprogramming technologies, reagents, and iPSC-derived cell types (Stemgent). With our deep knowledge of stem cell biology, bioengineered (3D) tissue models (Alvetex) cell differentiation, and pharmacology, REPROCELL is a recognized leader in cutting-edge tools and services to accelerate regenerative medicine and drug development. The newly formed REPROCELL Medical business unit is developing a suite of reagents and services to meet the growing need for clinical-grade products and services that are appropriate for regenerative medicine. In addition, our labs offer diagnostic services for a variety of tests related to tissue compatibility and other biomarkers. And finally, REPROCELL also offers a GMP iPSC master cell bank manufacturing service. *** REPROCELL went public on the Japan JASDAQ in June 2013. Stemgent, BioServe and Reinnervate became parts of REPROCELL in 2014. Biopta was then acquired in 2015.
REPROCELL revenue & valuation
| Annual revenue | $13,600,000 |
| Revenue per employee | $219,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $43,300,000 |
| Total funding | $556,100 |
Employees by Management Level
Total employees: 51-100
Seniority
Employees
Employees by Department
REPROCELL has 28 employees across 8 departments.
Departments
Number of employees
REPROCELL Tech Stack
Discover the technologies and tools that power REPROCELL's digital infrastructure, from frameworks to analytics platforms.
Cookie compliance
Security
CMS
Maps
CDN
Marketing automation
Advertising
JavaScript frameworks
Analytics
Miscellaneous
Security
France
Albania
CanadaFrequently asked questions
4.8
40,000 users
